China Allergy Drug Market Report

Statistic data indicate that the Chinese incidence of allergy diseases is as high as 37.3%. The incidences of allergy in the eastern coastal regions are higher than that in the inner land. The incidences of allergy in industrialized regions are higher than that in the rural areas. Under the government pricing control policies, the market growth of the allergy drugs has slowed down significantly in 2007. The sales of allergy drugs is about RMB 3.9 billion (USD 557 million) with only 2.63% same period growth in 2007 The allergy drug market has intense competitions. The market shares from the top 20 companies account for about 88.44% of the Chinese hospital allergy drug market in 2007, which is similar to the situation in 2006. The No.1 Company is still Schering-Plough, taking XX% of the total Chinese allergy drug market. Ioratadine and desloratadine are the two key allergy products from Schering-Plough. However, many generic products have recently been introduced in the market and have intensified the market competition. The market shares of Schering-Plough have been diluted greatly and have declined from 2006. Xian-Janssen is the No.2 player with XX% of the market. Xian-Janssen's strong position in the allergy drug market is supported by the strong growth of its core allergy drug mizolastine. UCB is the 3rd player in 2007 with XX% of the market, fueled by its new product levocetirizine.

This report has systemically analyzed the Chinese allergy drug market. All drug data are based on hospital drug prescription and drug purchasing data from the hospital data monitor system that the China Nan Fang Institute of Medical and Economic Information has developed and maintained (Nan Fang Institute is a direct subsidiary of the Chinese State Food and Drug Administration, the SFDA). Sampled hospitals are from major Chinese cities across different geographic locations, including Beijing, Shanghai, Guangzhou, Nanjing, Chengdu, Chongqing, Xian, Shenyang, Harbin and Zhengzhou, covering significant percentages of all hospitals in these regions.
Market shares from all major players including multinational and Chinese pharmaceutical companies and their major allergy products are analyzed systemically based on data from significant number of Chinese hospitals. The comprehensive hospital utilization data of major allergy drugs will present you a clear picture of the competition landscape of Chinese allergy drug market and the market potential for your company's product(s) that already marketed in China or if you are planning to bring your drugs to the China market.

This China Allergy Drug Market Report has been a Must-have reference for all levels of decision makers in pharmaceutical companies, medical device companies, healthcare investing companies and healthcare consulting companies. These unique drug prescription and utilization data can provide valuable information for new product development, marketing and strategic planning functions for pharmaceutical companies. Compared to expensive customized drug reports in China, this multi-client report provides significant savings and great cost/benefit to pharmaceutical companies and interested parties.